Find clinical trials for Glioblastoma (GBM) in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Glioblastoma

Recurrence

Brain Cancer

Glioma

Cancer

Astrocytoma

Gliosarcoma

Glioblastoma (GBM) trials near Nashville, TN, USA:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM...

Active, not recruiting

Glioblastoma

Glioblastoma Multiforme

Drug: Dendritic cell immunotherapy

Phase 3

Northwest Biotherapeutics

Nashville, Tennessee, United States and 85 other locations

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent glioma...

Active, not recruiting

Glioblastoma

Adult-type Diffuse Gliomas

Drug: Pemigatinib

Phase 2

Incyte

Nashville, Tennessee, United States and 80 other locations

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32)

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM...

Active, not recruiting

Glioblastoma Multiforme

Device: Optune®

NovoCure

Nashville, Tennessee, United States and 132 other locations

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expr...

Enrolling

Advanced Non-Small Cell Squamous Lung Cancer

Epidermal Growth Factor Receptor C797S

Drug: BDTX-1535 monotherapy

Phase 1, Phase 2

Black Diamond Therapeutics

Nashville, Tennessee, United States and 24 other locations

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, o...

Enrolling

Glioblastoma Multiforme

Drug: Carmustine

Biological: VBI-1901

Phase 1, Phase 2

VBI Vaccines

Nashville, Tennessee, United States and 11 other locations

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy o...

Enrolling

Glioblastoma

Glioblastoma Multiforme

Drug: Temozolomide

Drug: ST101

Phase 1, Phase 2

Sapience Therapeutics

Nashville, Tennessee, United States and 11 other locations

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an...

Enrolling

Locally Advanced Solid Tumor

Drug: TNG908

Phase 1, Phase 2

Tango Therapeutics

Nashville, Tennessee, United States and 15 other locations

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

* To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM...

Active, not recruiting

Glioblastoma Multiforme

Drug: ERAS-801

Phase 1

Erasca

Nashville, Tennessee, United States and 7 other locations

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

To assess:* efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification...

Enrolling

Glioblastoma Multiforme

Brain Tumor

Drug: APL-101 Oral Capsules

Phase 2

Apollomics

Nashville, Tennessee, United States and 90 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Glioblastoma (GBM) in .css-epvm6{white-space:nowrap;}Nashville, TN

Related conditions:

Glioblastoma (GBM) trials near Nashville, TN, USA:

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32)

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Find clinical trials for Glioblastoma (GBM) in Nashville, TN